💸 The Tape

Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) has now announced three acquisitions in eleven days, which is either admirable conviction or a company that has discovered the "buy" button and can't find the "stop." Friday's entry: four separate definitive purchase agreements — with FarmaceuticalRx LLC, FarmaceuticalRx 2 LLC, CAOH LLC and Canoe Hill Ohio, LLC — to acquire eight dispensaries, a cultivation and processing facility and related real estate, establishing a vertically integrated platform in Ohio.

The price tag is $208 million, and the currency is worth noting: the consideration will be satisfied entirely by issuing roughly 11 million subordinate voting shares, delivered in three tranches — 50% at closing, 25% at about 90 days, and the final 25% at about 180 days. The deferred portions are tied to continued performance of the acquired businesses, with a forfeiture mechanism letting Vireo claw back up to 25% of the shares if specified thresholds aren't met. Closing is expected in Q4 2026. Vireo Growth Inc. Announces a Four-Deal Transaction to Establish Presence in Ohio.

Structuring an all-stock deal with staged delivery and a clawback is the correct way to buy assets you haven't operated yet. Credit where due — this is more seller-alignment than most cannabis M&A bothers with.

The governance asterisk

One item deserves daylight rather than a footnote. CEO John Mazarakis is himself a seller under the CAOH LLC agreement. He declared the conflict, recused himself from all board deliberations and voting, and the other sellers are arm's-length. The deal qualifies as a related-party transaction under MI 61-101, and Vireo intends to rely on exemptions from both the formal valuation requirement and the minority approval requirement, on the basis that the interested-party portion doesn't exceed 25% of market capitalization. No shareholder approval is expected.

Everything there is procedurally clean. It also means a $208 million purchase that partly enriches the CEO clears without an independent valuation or a minority vote. That's not an accusation — it's a disclosure item investors should price rather than skim.

The roll-up in full

Zoom out and the Ohio deal is one tile in a much larger mosaic. Vireo announced an agreement to acquire Planet 13 Holdings on July 27 — a deal it says would make Vireo the largest U.S. operator by dispensary count — after agreeing on July 20 to acquire certain assets of The Cannabist Company. Stack them together and Vireo expects a presence in 16 states with roughly 270 dispensaries, up from 10 states and about 170 today, plus single dispensary licenses in Pennsylvania and Nevada.

That is a 60% increase in store count in under two weeks of announcements. The integration risk here is not theoretical.

Why Ohio, and why now

Here's where the strategy gets defensible, because Ohio is arguably the best-constructed limited-license market in the country right now — and it got that way in March.

Vireo notes Ohio recently surpassed $1 billion in combined medical and adult-use sales and remains one of the fastest-growing markets in the country. But the number that actually matters is the one nobody put in the release: supply is capped.

Senate Bill 56, effective March 20, 2026, set a statutory cap of 400 dispensaries statewide under a unified Division of Cannabis Control, with buffer requirements from schools, playgrounds and churches. In a capped market, a license stops being an operating permit and starts being an appreciating asset. $208 million for eight stores and a grow looks expensive against a per-door average — until you notice the doors are non-replicable.

Then there's the hemp piece, which is the real story. SB 56 reclassified any product containing more than 0.4 milligrams of total THC per container as marijuana, meaning delta-8 gummies, THCA flower and THC beverages can no longer be sold at gas stations, smoke shops or convenience stores — they're restricted exclusively to licensed dispensaries. Governor DeWine went further than his own legislature: SB 56 originally carved out 5mg THC beverages through the end of 2026, and he line-item vetoed it, saying a carve-out would create consumer confusion and conflict with federal law. The industry's counterpunch missed — Ohioans for Cannabis Choice failed to gather enough signatures for a November referendum, letting the law stand.

Put plainly: Ohio capped the number of licensed sellers and simultaneously deleted their unlicensed competition. Every hemp dollar formerly spent at a Circle K is now a dispensary dollar or an illicit one. That is the single most operator-friendly regulatory combination in the country, and it explains why capital is flowing toward Ohio licenses rather than away from them.

Jushi already showed you the math

You don't have to model this. Someone reported it Tuesday.

Jushi Holdings disclosed that Ohio contributed $4.6 million in incremental retail revenue in Q2 on three new dispensaries — the largest single-market contribution in a quarter where total company revenue grew 10%. Three stores. In a market where the hemp channel had been closed for roughly ten weeks.

Jushi's broader print showed retail revenue up just 4% on units up 11.4% — heavy price compression across its footprint. Ohio was the exception that carried the quarter. That's the read-through: in states where licensed operators aren't competing with gas-station THC, the volume growth actually converts to revenue.

Vireo isn't guessing at Ohio's unit economics. It's buying into a market that a competitor just validated in public.

The catch

Two of them. First, local opt-outs are real: 137 Ohio jurisdictions had active moratoriums as of May 1, covering roughly 14% of the state's population, and 106 of those bans carry no defined end date — though Ohio's opt-out rate remains modest against Michigan's 73% and New York's roughly 50%, and the Host Community Fund distributes 36% of adult-use excise tax only to localities that permit dispensaries, which is a fairly direct financial nudge.

Second, Vireo is paying in its own stock, three announcements deep, before integrating any of it. The clawback protects against seller underperformance. Nothing protects against buyer indigestion.

Ohio is the right market. 270 dispensaries in sixteen states is the question.

📈 Dog Walkers

$GTBIF ( ▲ 1.89% ) Expands In PA

Green Thumb Industries (CSE: GTII) (OTCQX: GTBIF) opened RISE Dispensary Hanover on Friday, adding a twentieth Pennsylvania location to a footprint the company has been building since 2017. The store sits at 361 Eisenhower Drive in Hanover, serving York and Adams Counties, with a grand opening slated for late August.

The product set is the full house lineup — RYTHM premium flower, vapes and concentrates, Good Green flower, (inc)ensored troches and Doctor Solomon's topicals — all supplied from Green Thumb's manufacturing facility in Danville. President Anthony Georgiadis called Pennsylvania a priority market, which the store count already made fairly clear. Per RISE tradition, first-day profits go to Friends & Neighbors of Pennsylvania, York County's only comprehensive street outreach organization for people facing homelessness.

The timing is the interesting part. This lands four days before Green Thumb reports Q2 results on August 4 — and Pennsylvania is precisely the market investors should be watching.

Why: Jushi reported Tuesday that retail revenue grew just 4% while units sold rose 11.4% — roughly seven points of price compression across a footprint anchored in Pennsylvania. Volume is there. Price is not. Adding a store into that environment is a share-capture play, not a market-growth one, and the operator with in-house manufacturing and vertical margin is better built to win it than a leveraged competitor.

Green Thumb has the balance sheet for that fight, closing Q1 with $274.3 million in cash and buying back $33.3 million of stock.

Twenty stores in a state still limited to medical patients is a considerable bet on Pennsylvania eventually going adult-use. RISE now operates over 120 locations across 14 markets. Tuesday tells us what the model is earning while it waits.

📺 Trade To Black

The DEA Requirements Nobody Talks About | Trade to Black

• The DEA and the FDA are asking completely different questions. Deepank frames the DEA as an inventory management system — tracking every milligram of controlled substance moving in and out of a facility — while the FDA owns product quality and safety. Two agencies, two entirely separate compliance burdens.

• Vantage built for DEA control from day one. The distinction matters because retrofitting an existing facility to GMP and DEA standards essentially doesn't work. Design decisions made at the outset determine whether pharma-grade compliance is achievable at all.

• Real GMP means quality is built in, not tested in. In practice that runs from equipment qualification and risk analysis through preventative maintenance and full documentation — quality engineered at the first step rather than inspected at the last.

• Rescheduling opens a genuine FDA drug approval pathway. Deepank explains why that changes the opportunity set, and why exporting under this level of compliance is a fundamentally different undertaking than operating domestically.